Lakewood-Amedex Biotherapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
8031 Cooper Creek Blvd Ste 103, Universi...Phone Number
(941) 225-2515Website
www.lakewoodamedex.comRevenue
-Stock Symbol
LABTIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Lakewood-Amedex Biotherapeutics
Lakewood Amedex Biotherapeutics is a biotechnology company focused on developing innovative antimicrobial therapies to address the growing challenge of antibiotic resistance. Its research centers on the Bisphosphocin® class of antimicrobials, which is designed to rapidly target and disrupt microbial membranes at the site of infection. The company’s development efforts include treatments for difficult-to-manage infections such as infected diabetic foot ulcers, with the broader goal of providing locally delivered therapies that can combat resistant bacteria and fungi while addressing unmet needs in infection management.Explore more
Lakewood-Amedex Biotherapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lakewood-Amedex Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Lakewood-Amedex Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Lakewood-Amedex Biotherapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Lakewood-Amedex Biotherapeutics
Check out if Lakewood-Amedex Biotherapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Lakewood-Amedex Biotherapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check if Lakewood-Amedex Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Lakewood-Amedex Biotherapeutics launches new products
Earning: See what the market has to say on Lakewood-Amedex Biotherapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Lakewood-Amedex Biotherapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Lakewood-Amedex Biotherapeutics
Compare insights from companies similar to Lakewood-Amedex Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lakewood-Amedex Biotherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lakewood-Amedex Biotherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lakewood-Amedex Biotherapeutics.
Lakewood-Amedex Biotherapeutics financials insights
Gather financial insights about Lakewood-Amedex Biotherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$5.5M
2026
Stock/Share Issuance
$7.5M
Lakewood-Amedex Biotherapeutics Tech Stack
A closer look at the technologies used by Lakewood-Amedex Biotherapeutics
Most Recent Scoops
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Executive Moves, Board of Directors
Promotion
Executive Move
Executive Moves, Promotion
Promotion
Executive Move
Executive Moves, Promotion
Lakewood-Amedex Biotherapeutics News & Media
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
Initiation of patient dosing marks significant clinical development milestone for Nu-3 and Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin® antimicrobial platform Topline data expected in the first quarter of 2027 SARASOTA, Fla., Sept. 24, 2026 /PRNewswire/ -- Lakewood-Amedex...Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
Clinical and Corporate Highlights Successfully listed on the Nasdaq Capital Market under the ticker symbol LABT, marking a significant milestone in the Company's evolution Strengthened balance sheet through completion of a $7.5 million private placement to support continued clinical...Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
SARASOTA, Fla., Sept. 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class,...Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
SARASOTA, Fla., Sept. 8, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lakewood-Amedex Biotherapeutics
Sign Up For FreeTo access detailed company insights
Lakewood Amedex Biotherapeutics is a biotechnology company focused on developing innovative antimicrobial therapies to address the growing challenge of antibiotic resistance. Its research centers on the Bisphosphocin® class of antimicrobials, which is designed to rapidly target and disrupt microbial membranes at the site of infection. The company’s... Read More
